Partner and Co-Founder
Lux CapitalCheck size: No personal check-size range is published. Lux invests early and can support companies across their development, but its USD 7B under management and individual financing totals are not Peter's personal allocation limits.
Peter seeks scientifically and technologically ambitious ventures attempting what most people think will not work but could become indispensable if they succeed. He is a generalist across technology and healthcare, with a particular record in multidisciplinary platforms—robotics, software, data, imaging, AI, and biology—that expand human capability, create new categories, and convert substantial technical risk into outsized societal and economic value.
Counter-conventional founders, scientific ambition, an apparently impossible technical goal with enormous payoff, interdisciplinary teams, platform innovation rather than a point device, persistence through disbelief, measurable patient or societal outcomes, and technology that becomes so useful it is eventually taken for granted.
His writing implies weaker fit for imitation, incremental products, buzzwords without enabling technology, insular domain teams unable to combine disciplines, founders whose conviction cannot survive rigorous criticism, and medtech point products without high-growth platform characteristics or meaningful patient impact. These are inferred from his stated thesis, not a formal list.
State the thing experts believe cannot work, why you know otherwise, and why success would create an indispensable platform or category. Bring the scientific evidence, risk-retirement sequence, interdisciplinary team, regulatory and manufacturing plan, capital milestones, and commercial wedge. Show how each technical milestone converts risk into value and how the platform expands beyond its first product.
Ask what informed skeptics believe cannot work, what evidence makes the team disagree, and whether technical success would create a capability important enough to become everyday infrastructure.
Sequence scientific, engineering, regulatory, manufacturing, adoption, and financing risks into milestones where each completed step materially increases evidence and enterprise value.
Determine whether the company fuses the necessary scientific, software, hardware, clinical, and commercial disciplines into a reusable platform rather than a single constrained product.
Evaluate whether modern AI, robotics, sensing, automation, or data changes clinical decisions, intervention, access, outcomes, and business scalability—not merely digitizes an old medical workflow.
Digitizing a largely offline physical asset class can create a large data and software platform when purpose-built capture technology meets an enormous underpenetrated market.
The next major health companies will combine medicine with AI, robotics, automation, machine vision, data, and modern platform economics rather than remain isolated medtech products.
Founders should critically process skepticism but persist when evidence still supports a counter-conventional insight; outsized outcomes often require sustained conviction through disbelief.
Ambitious multidisciplinary teams can translate medical robotics through regulatory approval into platforms that enhance physicians, enable new care categories, and improve patient outcomes.
No podcast appearances are linked yet. Ask Kit to check for interviews that reveal how this investor thinks.
Quote coverage is incomplete. Kit can look for direct comments on markets, founders, and investment criteria.
Peter co-founded Lux Capital and in 2003 led the spinout of Lux Research as its founding CEO. He later co-founded Thematic, an index and ETF developer. He began in Lehman Brothers' equity-research group, graduated cum laude from Syracuse University's Newhouse School as a Chancellor's Scholar, and founded the school's first venture organization. Lux attributes major investments and exits to him including Auris Health, Everspin, Flex Logix, Luxtera, Matterport, Transphorm, and Vium.